Emicerfont

Drug Profile

Emicerfont

Alternative Names: 876008; GW 876008; GW876008X

Latest Information Update: 14 Aug 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline; Neurocrine Biosciences
  • Developer GlaxoSmithKline
  • Class Antidepressants; Anxiolytics; Irritable bowel syndrome therapies; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Irritable bowel syndrome; Major depressive disorder

Most Recent Events

  • 25 Nov 2009 Pharmacodynamics data from a phase II trial in Irritable bowel syndrome presented at GASTRO 2009 Joint Meeting (GASTRO-2009)
  • 30 Sep 2009 Clinical development is ongoing in USA
  • 05 Feb 2008 GlaxoSmithKline completes enrolment in its Phase-II trial for Irritable bowel syndrome in the US and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top